StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3085% above fair value
$286.00−2.84 (-0.98%)

Close on Nov 3, 2026Market cap $505.40BP/E 80.8Yield 2.33%

AbbVie Restructuring Reserve Liability [legacy through FY20Q1] by Year

Restructuring Reserve Liability [legacy through FY20Q1] ($M) ($M)

AbbVie Restructuring Reserve Liability [legacy through FY20Q1]: $140M in FY2019, up 41.4% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2019
140
Period ended Dec 31, 2019
Change on a year earlier
+41.4%
99 in FY2018
History
5 years
Since FY2015
Sources
3
Documents cited below

Where the FY2019 figure comes from

Source: Form 10-Q (filed 2020-05-08) ↗

Reported in Form 10-Q / 10-K Restructuring Note.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRestructuring Reserve Liability [legacy through FY20Q1] ($M) ($M)Year on yearSource
FY2019Dec 31, 2019140+41.4%Form 10-Q (filed 2020-05-08) ↗
FY2018Dec 31, 201899+15.1%Form 10-K (filed 2020-02-21) ↗
FY2017Dec 31, 201786-1.1%Form 10-K (filed 2020-02-21) ↗
FY2016Dec 31, 201687-41.2%Form 10-K (filed 2020-02-21) ↗
FY2015Dec 31, 2015148–Form 10-K (filed 2019-02-27) ↗

Cite this data

StockData. (2026). AbbVie Restructuring Reserve Liability [legacy through FY20Q1] ($M), annual FY2015–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/restruct-res-leg

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?